The role of autologous hematopoietic cell transplantation (auto-HCT) in the management of indolent non-Hodgkin lymphomas (NHL) is shrouded in controversy. The outcomes of conventional therapies for many indolent lymphoma subtypes have dramatically improved over the last several years with the use of monoclonal antibodies, maintenance therapy programs and with the incorporation of radio-immunoconjugates. These significant advances in the armamentarium of lymphoma therapeutics warrant reappraisal of the current role of auto-HCT in the treatment algorithm of indolent NHL. Prospective randomized studies comparing contemporary chemoimmunotherapies against auto-HCT are lacking, leading to significant debate about the role and timing of auto-HCT for indolent NHL in the modern era. Although autografting for follicular lymphoma (FL) in first remission has been largely abandoned, it remains a useful modality for relapsed disease, especially for the subgroup of patients who are not candidates for allogeneic transplantation with a curative intent. Auto-HCT can provide durable disease control in chemosensitive transformed FL and mantle cell lymphoma (MCL) in first remission, with relatively low toxicity, and remains appropriate in chemoimmunotherapy era. Contemporary data are also reviewed to clarify the often underutilized role of autografting in relapsed MCL and other less frequent indolent NHL histologies. The biological basis of the increased risks of second malignancies with auto-HCT are reviewed to identify strategies designed to mitigate this risk by, for example, avoiding exposure to genotoxic agents, planning early stem cell collection/cryopreservation and minimizing the use of TBI with transplant conditioning, and so on. Genetic testing able to identify patients at high risk of therapy-related complications and novel post-transplant immune therapies with the potential of transforming autografting in indolent NHL from a remission-extending therapy to a curative modality are discussed to examine the possibly expanding role of auto-HCT for lymphoid malignancies in the coming years. Keywords: follicular lymphoma; mantle cell lymphoma; Waldenströ m macroglobulinemia; autologous transplantation; second malignancies INTRODUCTION High-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) is considered a standard therapy for patients (age p65-75 years) with relapsed chemosensitive aggressive non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma, and appears to be curative for B40-45% of the patients.
INTRODUCTION
High-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) is considered a standard therapy for patients (age p65-75 years) with relapsed chemosensitive aggressive non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma, and appears to be curative for B40-45% of the patients. [1] [2] [3] [4] The role of auto-HCT in the management of patients with indolent NHL is more contentious. Results of conventional therapies for many indolent lymphoma subtypes have dramatically improved over the last several years with the use of monoclonal antibodies, namely rituximab 5, 6 and radio-immunoconjugates. 7 These significant advances in the armamentarium of lymphoma therapeutics warrant reappraisal of the current role of HDT and auto-HCT in the treatment algorithm of indolent NHL. Unfortunately, prospective randomized studies comparing contemporary chemoimmunotherapies against auto-HCT are lacking, leading to significant controversy regarding the role and timing of auto-HCT in patients with indolent NHL. Moreover, although HDT and auto-HCT in indolent histologies has low TRM and morbidity, there is a continuous risk of disease relapse after autografting, and concerns about the long-term toxicities associated with this approach, especially the development of secondary myelodysplastic syndrome (sMDS)/AML. 8 This review focuses on available data from the pre-rituximab and rituximab eras to clarify the role and optimal timing of auto-HCT among indolent B-cell NHLs, including follicular lymphoma (FL), transformed FL, mantle cell lymphoma (MCL), Waldenströ m macroglobulinemia (WM), marginal zone lymphoma (MZL) and small lymphocytic lymphoma (SLL).
FOLLICULAR LYMPHOMA FL is the second most common type of NHL, accounting for about 22% of the cases. 9 The disease course in FL is one of remissions and relapses with conventional therapies, followed not infrequently by development of resistance or transformation into a more aggressive histology. Management strategies include surveillance, immunotherapy, combination chemoimmunotherapy, radioimmunotherapy consolidation and autologous or allogeneic transplantation.
AUTOLOGOUS HCT FOR FL IN FIRST REMISSION
To improve the depth of response, disease control and possibly survival, the role of auto-HCT consolidation for FL patients in first remission has been extensively investigated. The Dana-Farber Cancer Institute data, demonstrating prolonged disease-free survival (43% at 12 years) in patients undergoing purged BM transplants, provided preliminary evidence for auto-HCT consolidation for FL in first remission. 10 Table 1 summarizes the four randomized clinical trials addressing the role of auto-HCT consolidation for FL in first remission. [11] [12] [13] [14] In a German (German Low Grade Lymphoma Study Group (GLSG)) and two French (Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest-Est des Leucé mies et Autres Maladies du Sang (GOELAMS)) cooperative group studies, advanced stage FL patients in first remission were randomized to receive either consolidation with auto-HCT or IFN maintenance. 11, 12, 14 As shown in Table 1 , auto-HCT provided a significant PFS benefit in the GLSG and GOELAMS trials, but not in the GELA study. Although none of these three studies reported an OS benefit with auto-HCT consolidation, in the GLSG trial, autografting was associated with a significantly higher risk of sMDS/AML. 11 Similarly, a significantly higher rate of second cancers was also noted in the GOELAMS study following auto-HCT.
14 Moreover, as these three trials were conducted in the pre-rituximab era, the applicability and relevance of these data for current clinical practice is not known. This is important, as the PFS of FL patients treated with rituximab containing first-line chemoimmunotherapies in the contemporary cooperative group trials is roughly similar to the PFS reported in auto-HCT arm of GELA and GLSG studies. 6, 15, 16 To address the role of upfront auto-HCT consolidation for FL in the rituximab era, the Gruppo Italiano Trapianto di Midollo Osseo/ Intergruppo Italiano Linfomi trial compared chemoimmunotherapy with R-CHOP (rituximab-CHOP) against rituximab-supplemented HDT and auto-HCT. In line with the pre-rituximab era data, in this study, auto-HCT improved PFS without an OS benefit and was associated with a trend toward more sMDS/AML (Table 1) . 13 Two recent meta-analyses of aforementioned trials also confirm the improved PFS with auto-HCT for FL in first remission, without any OS benefit. 17, 18 Recommendations Although keeping in perspective the recent advances in the management of FL, including radioimmunotherapy consolidation, 7 rituximab maintenance 5 or re-treatment, 19 the routine use of auto-HCT for FL in first remission is not recommended, especially considering its associated risk of secondary malignancies and the lack of a clear OS benefit.
AUTOLOGOUS HCT FOR RELAPSED/REFRACTORY FL
Although FL patients generally respond to initial therapy, disease relapse unfortunately is inevitable. The role, optimal timing and preferred transplant modality (autologous versus allogeneic) in the relapsed setting remain a matter of controversy. Although auto-HCT has long been available for patients with relapsed chemosensitive FL, 20, 21 large randomized studies establishing superiority of auto-HCT over salvage chemoimmunotherapy alone are not available. The European Blood and Marrow Transplant (EBMT) group performed the only randomized clinical trial in this setting (CUP trial). The CUP trial compared salvage chemotherapy alone with chemotherapy followed by either purged or unpurged auto-HCT in relapsed FL. This trial was closed prematurely because of poor accrual, but despite the small number of patients enrolled (n ¼ 89), it showed a significant PFS and OS benefit with auto-HCT. 22 There was no significant difference in the outcomes of purged compared with unpurged autografts. However, the current clinical relevance of this trial is questionable, as it was conducted before the advent of contemporary chemoimmunotherapies.
To investigate whether auto-HCT offered any benefit over chemotherapy alone in the rituximab era, Sebban et al. 23 conducted a post-hoc analysis of patients enrolled in two consecutive GELF (Groupe d 0 Etude des Lymphomes Folliculaires) protocols, who subsequently relapsed and received various salvage therapies (including auto-HCT). In patients who received rituximab-based salvage therapies, no statistically significant OS benefit was seen with auto-HCT (93% at 5 years) when compared with patients getting salvage chemoimmunotherapy alone (70% at 5 years). 23 In a different study, the combined retrospective data from Dana-Farber Cancer Institute and St Bartholomew's Hospital, suggested prolonged remissions in relapsed FL patients after auto-HCT; however, this benefit was restricted primarily to patients in second CR. 24 Theoretically, auto-HCT could routinely be justifiable at such an early point in relapsed FL, if it was curative and devoid of serious complications. Auto-HCT unfortunately is not generally considered a curative modality for FL. Large registry data from EBMT 25 and Center for International Blood and Marrow Transplant Research (CIBMTR) show no plateau in relapse rates post autografting. 26 More importantly, the risk of second malignancies post auto-HCT is not insignificant, ranging from 5-15% in several large studies. 24, 25 Table 2 summarizes the major retrospective studies addressing the role of auto-HCT in relapsed FL. [23] [24] [25] [26] [27] [28] [29] Disease relapse post auto-HCT in FL occurs via two possible mechanisms. Majority likely relapse due to the proliferation of a chemoresistant clone of lymphoma cells (or stem cells) surviving the HDT. A minority, where HDT is truly able to eradicate the disease in the patient, may experience relapse due to re-infusion of a stem cell product contaminated by lymphoma cells at the Autografting for B-cell lymphomas M Hamadani time of transplantation. To circumvent the problem of autograft contamination by lymphoma cells, several studies have examined the role of ex vivo purging (by monoclonal antibodies, CD34 þ cell selection and so on) 30, 31 and in vivo purging (for example, rituximab with mobilization) 27, 32 of autologous stem cell products with encouraging results. However, the lack of randomized data to prove the superiority (or curative potential) of purged auto-HCT 22 and a possible increase in infectious complications with ex vivo purging 33, 34 have prevented the uniform adoption of this approach by transplant centers. Whether post auto-HCT rituximab maintenance will improve patient outcomes is an area of active investigation and it is best not to consider this a standard option currently. 35 Another challenging question encountered in the clinic is whether to offer auto-HCT or allo-HCT to FL patients relapsing after multiple prior lines of therapies. Although the discussion of allo-HCT is beyond the scope of this review, suffice it to say that an adequately powered prospective trial comparing these two options is lacking. Unfortunately, the key BMT CTN (Bone Marrow Transplant Clinical Trials Network) trial comparing auto-HCT with reduced-intensity conditioning allo-HCT in FL was closed because of poor accrual. 36 
Recommendations
In the rituximab era, the lack of randomized data establishing the superiority of autografting over salvage chemoimmunotherapy alone makes it difficult to recommend the routine use of auto-HCT in relapsed FL. The decision to offer an auto-HCT for relapsed FL should take into account several factors, including patient age, associated comorbidities, risk of secondary cancers and presence of chemosensitive disease. Auto-HCT should not be offered to heavily pretreated patients with refractory disease. Auto-HCT is best reserved for chemosensitive, relapsed FL patients after two to three lines of prior chemoimmunotherapies (ideally at least one doxorubicin-based line and a bendamustine-based regimen), who are not candidates for curative therapies, namely allo-HCT, either because of donor unavailability, associated comorbidities or patient preference.
AUTOLOGOUS HCT FOR TRANSFORMED FL
Transformation of FL to an aggressive histology is not uncommon. 37 Studies evaluating the role of HCT in this setting are limited because of their retrospective nature, lack of randomized data and by the heterogeneity of criteria used to define histologic transformation (with some studies including grade III FL). Table 3 summarizes selected studies evaluating the role of auto-HCT in transformed FL. [38] [39] [40] [41] [42] The EBMT reported the largest study, involving 50 patients with chemosensitive disease. The 5-year PFS and OS were 30 and 51%, respectively. 39 The Norwegian group recently published the only prospective trial of auto-HCT in Purged Autografting
42 Short follow-up and patient selection (with majority of patients with minimal disease before transplantation) is a limitation to consider when interpreting these results. No randomized data are available to show whether patients with limited-stage disease at the time of transformation derive any added benefit from auto-HCT consolidation, as these patients can experience prolonged remissions with chemoimmunotherapy alone. 37 An often overlooked issue in transformed FL is late relapses with the indolent non-transformed component post auto-HCT, indicating that although HDT may eradicate the large cell component, the FL (non-transformed) remains incurable.
Recommendations
With the limitations discussed above in mind, auto-HCT is appropriate for transformed FL patients with non-bulky (ideally no nodal areas X3 cm in size) chemosensitive disease.
MANTLE CELL LYMPHOMA MCL accounts for B6% of NHLs and typically presents with advanced-stage disease that frequently involves extranodal sites. 43 Over the last decade, multi-agent chemoimmunotherapies, either alone 44 or as an induction followed by auto-HCT consolidation in first remission [45] [46] [47] or rituximab maintenance, 48 have produced higher response rates and improved outcomes. Although these modalities have improved the prognosis of MCL, 49 disease relapse remains problematic.
AUTOLOGOUS HCT FOR MCL IN FIRST REMISSION
The poor prognosis of relapsed MCL (median survival of B1-2 years) 50 serves as a rationale for auto-HCT consolidation in first remission. Early registry data from EBMT and ABMTR (Autologous Bone Marrow Transplant Registry) supported the role of auto-HCT for MCL in first remission, particularly for patients in CR1 (5-year PFS and OS of 52 and 65%; respectively). 51 These results were subsequently confirmed by the European MCL Network trial, which randomized MCL patients after first-line induction with CHOP-like regimens to either auto-HCT consolidation or IFN maintenance (Table 4) . 45 Auto-HCT in this study provided a superior PFS, but no survival benefit was seen.
Randomized data, of the likes of European MCL Network study, to guide therapy in the rituximab era are not available. Several phase II studies have however reported favorable outcomes with upfront auto-HCT consolidation in MCL in the chemoimmunotherapy era 46, 47, 52, 53 (Table 4 ). The CALGB (Cancer and Leukemia Group B) reported encouraging results with upfront auto-HCT in MCL patients, following RM-CHOP induction and in vivo purging with rituximab during chemomobilization. 46 In the largest prospective study to date, the Nordic Lymphoma Group (MCL-2 trial) 47 reported impressive results with an intensive induction regimen, followed upfront auto-HCT with rituximab-purged stem cells (6-year PFS of 66%), with only a few late relapses on long-term follow-up. 54 MCL-2 results compare favorably with the results of the older MCL-1 trial (CHOP followed by auto-HCT) by the same group, where 4-year PFS was only 15%. 55 A likely explanation of this difference is the addition of cytarabine in intensified induction and in vivo purging with rituximab during stem cell mobilization in the MCL-2 study. Ongoing South West Oncology Group (SWOG; R-bendamustine versus R-Hyper-CVAD; NCT01412879) and European MCL Network (R-CHOP versus R-CHOP/R-DHAP; NCT00209222) trials will hopefully clarify the optimal induction approach before auto-HCT.
Although the aforementioned prospective studies establish the feasibility and efficacy of upfront auto-HCT in MCL, it is important to acknowledge that although this modality is widely practiced, it is not uniformly accepted by all centers. Mature data from the MD Anderson Cancer Center suggest that chemoimmunotherapy with R-Hyper-CVAD (rituximab, fractionated CY, vincristine, doxorubicin, dexamethasone alternating with methotrexate and cytarabine) without an auto-HCT consolidation might be an effective strategy for MCL, with 7-year OS and PFS of 60 and 43%, respectively. 44 These excellent outcomes with R-Hyper-CVAD, however, were not reproduced in a multicenter SWOG study. 56 A provocative analysis from Budde et al., 57 suggests that the prognosis of MCL is not governed by the intensity of induction therapy but rather by the disease biology, as reflected by poor outcomes of high-risk MIPI (Mantle Cell Lymphoma International Prognostic Index) patients, regardless of induction or consolidation strategy used. The poor outcomes of high-risk MIPI patients, with 58, 59 or without 44, 60 auto-HCT, have been reported by several other groups, underscoring the need for evaluating alternative consolidation modalities for such patients (for example, early use of allo-HCT).
Recommendations Acknowledging the lack of contemporary randomized data, upfront auto-HCT consolidation in MCL is a valid option, especially for patients with low-and intermediate-risk MIPI. Early stem cell Autografting for B-cell lymphomas M Hamadani collection (after three to four cycles) is strongly recommended in patients receiving R-Hyper-CVAD induction before a planned auto-HCT, as this regimen can impair stem cell mobilization. 61 Advanced age (65-75 years) alone should not preclude an auto-HCT in an otherwise healthy patients.
62,63
AUTOLOGOUS HCT FOR RELAPSED/REFRACTORY MCL Limited retrospective data have suggested that auto-HCT might not be an effective strategy for relapsed MCL in general 64, 65 and chemorefractory patients in particular. 51, 66, 67 The EBMT study showing that relapsed MCL patients were three times more likely to relapse after auto-HCT than patients in first remission, casted serious doubts about the role of this modality in relapsed disease. 51 However, recently, CIBMTR reported 5 year OS of 44% in 159 relapsed, chemosensitive MCL patients undergoing auto-HCT. 68 
Recommendations
In relapsed MCL patients with chemosensitive disease, who are not candidates of a potentially curative allo-HCT (due to comorbidities, donor availability and so on), consolidation with an auto-HCT can be offered, with the understanding that this therapy is not curative. HDT is not recommended for patients with refractory MCL.
AUTOLOGOUS HCT FOR WM
WM is an indolent B-cell lymphoproliferative disorder resulting from the accumulation of clonally related IgM-secreting lymphoplasmacytic cells. 69 Frontline therapy options for symptomatic WM patients include alkylators (for example, CY or chlorambucil), nucleoside analogs for example, fludarabine), rituximab, as well as combinations of these agents. 70, 71 No large prospective studies are available to support the use of auto-HCT consolidation for WM in first remission, and it should not be considered outside the setting of a clinical trial. Several small retrospective studies and registry data have examined the role of auto-HCT in mostly relapse/refractory WM. [72] [73] [74] [75] Dhedin et al. 76 retrospectively analyzed auto-HCT outcomes in 32 WM patients. Fifty percent of the patients had X3 lines of prior therapies. Median PFS was 32 months, with a 5-year OS of 58%. The EBMT reported auto-HCT outcomes in 158 WM patients. 77 The majority had chemosensitive disease, and 32% of the patients had received X3 lines of prior therapies. Five-year PFS and OS were 40 and 68%, respectively. Although TRM was low, the cumulative incidence of second malignancies was B8% at 5 years. The results of the SWOG-9805 (NCT00003416) trial will hopefully clarify the role of auto-HCT in relapsed WM in the coming years.
Recommendations
The limited retrospective data available currently suggest feasibility of auto-HCT in relapsed WM, with 4-to 5-year PFS of approximately 40-50%. 73, 74, 77 Auto-HCT can be considered in relapsed chemosensitive WM patients, after two to three lines of prior therapies (preferably consisting of at least one alkylator/anthracyclinebased regimen and a bortezomib-containing regimen). As purine nucleoside analogs (particularly fludarabine) can impair stem cell mobilization, their use in patients who are potential future candidates of an auto-HCT, should be avoided. 71, 78, 79 
AUTOLOGOUS HCT FOR MZLS AND SLLS
The role of auto-HCT in MZL is extremely controversial. Only a few, small retrospective case series for auto-HCT in MZL have been reported, 80, 81 showing PFS roughly similar to the ones reported for FL, with frequent late relapses. In multiple relapsed patients with chemosensitive disease, who are not candidates for clinical trials (or allo-HCT), consideration can be given to a salvage auto-HCT with a non-curative intent. The situation for SLL is no different, with virtually no prospective or large retrospective studies reported for this histology. Extrapolating the data from SLL's leukemia counterpart (that is, CLL), which showed no survival benefit with auto-HCT, [82] [83] [84] and considering the availability of highly active chemoimmunotherapies, 85 this modality cannot be recommended in patients with SLL off clinical trial.
SECOND MALIGNANCIES AND AUTOLOGOUS TRANSPLANTATION
The increased incidence of second malignancies, particularly sMDS/AML following auto-HCT, is well documented. 86 Factors associated with an increased risk of second cancers after auto-HCT include advanced patient age, 87 91 and use of TBI with transplant conditioning 87, 92 and so on. As most of these risk factors are not transplant-related (for example, patient age, prior therapies and so on), it is plausible that second malignancies post auto-HCT are primarily a result of genotoxic damage already incurred by the transplant recipients before autografting. Supporting this hypothesis are observations that mutations in certain 'leukemia pathway' genes (for example, RUNX1, TP53, NRAS, KRAS) [93] [94] [95] and polymorphisms in genes involved in drug metabolism 96 and DNA repair, 97 which are not transplant-related factors, are associated with an increased risk of sMDS/AML. However, the increased incidence of second malignancies in the auto-HCT arms of at least two randomized clinical trials involving patients with identical prior therapies 11, 14 suggest a causative role of HDT in the pathogenesis of this complication. The hematopoietic reconstitution after auto-HCT exerts a 'proliferative stress' on infused progenitor and stem cells. Increased proliferative stress on stem cells already bearing genotoxic damage (from prior therapies) may contribute to the pathogenesis of sMDS/AML by promoting genomic instability through shortening of telomeres in descendent cells. 86, 98 Limiting the exposure to leukemogenic agents before transplantation and use of non-TBI-based conditioning regimens are potential strategies to mitigate the risk of second malignancies post auto-HCT. Table 5 summarizes recommendations on the role of auto-HCT in indolent B-cell NHL and highlights potential future direction to improve outcomes. Areas of controversy and recommendations reflecting author's opinion and practice are indicated.
FUTURE DIRECTIONS
Routine use of peripheral blood products, post-transplant growth factor administration and modern supportive measures have undoubtedly improved the safety of auto-HCT in lymphoid malignancies and extended its availability to populations previously deemed unsuitable for this procedure. 62, 99, 100 Randomized trials clarifying the role and timing of auto-HCT against chemoimmunotherapy for indolent NHL, when urgently needed, are unlikely to be performed in the near future. Cooperative group efforts are needed to incorporate novel potentially curative strategies into modern auto-HCT, rather than solely focusing on therapies merely capable of extending remission duration, without impacting survival. Radioimmunotherapy-based conditioning regimens, despite their early promise, 101 are unlikely to achieve this goal. 102 Similarly, rituximab maintenance and/or consolidation post auto-HCT in patients previously not cured by rituximab-containing regimens may very well extend the PFS, but is unlikely to eradicate the residual disease permanently. 33, 103 Along similar lines, although stem-cell purging might provide a 'tumor-free' autograft, it cannot prevent the vast majority of relapses resulting from residual lymphoma cells surviving HDT in Autografting for B-cell lymphomas M Hamadani the transplant recipient. Many patients with aggressive NHL are after all cured with unpurged auto-HCT, highlighting the inability of HDT to permanently eradicate disease in indolent NHL.
Moving forward, efforts can be focused on evaluating novel consolidation or maintenance strategies, possibly with agents not used before HDT. CALGB is evaluating the role of bortezomib maintenance in MCL after auto-HCT (NCT00310037). Maintenance/ consolidation with immunomodulatory agents (for example, lenalidomide; NCT01035463) or newer B-cell monoclonal antibodies (for example, ofatumumab, MEDI-551 and so on) warrant investigation in post-transplant setting. Carefully designed protocols to evaluate novel modalities, such as 'immunotransplants' (in situ tumor vaccination followed by transplantation of harvested tumor-specific T cells), 104 post-transplant idiotype vaccination 105 and HDT's role as a lymphodepleting platform for chimeric Ag receptor T-cell therapy 106 are warranted to transform auto-HCT from a 'remission-extending' therapy to a curative modality in the coming years. Modified from Hake CR et al.
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